Cingulate Inc. (CING) Stock Ticker
CING right now
Market factors today
Unlock the full CING picture
About Cingulate Inc.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
CING stock facts
| Ticker symbol | CING |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $65.1M |
| CEO | Shane J. Schaffer |
| Employees | 14 |
| Headquarters | Kansas City, KS, US |
| IPO date | 2021-12-08 |
| Website | www.cingulate.com |
What you can see for CING on Tickr
Live CING price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CING report.
Rankings
FAQ
What is the ticker symbol for Cingulate Inc.?
The ticker symbol for Cingulate Inc. is CING, listed on the NASDAQ Capital Market.
What is CING?
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also…